Details
Stereochemistry | ACHIRAL |
Molecular Formula | C15H17ClN4O |
Molecular Weight | 304.775 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
ClC1=CC(COC2=NC(=CN=C2)N3CCNCC3)=CC=C1
InChI
InChIKey=PCWGGOVOEWHPMG-UHFFFAOYSA-N
InChI=1S/C15H17ClN4O/c16-13-3-1-2-12(8-13)11-21-15-10-18-9-14(19-15)20-6-4-17-5-7-20/h1-3,8-10,17H,4-7,11H2
Molecular Formula | C15H17ClN4O |
Molecular Weight | 304.775 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/16949622Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23049953
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16949622
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23049953
CP-809101 is a potent, functionally selective 5-HT(2C) agonist that displays approximately 100% efficacy in vitro. CP-809101 has a pharmacological profile similar to that of the atypical antipsychotics with low extrapyramidal symptom liability. CP-809101 was active in novel object recognition, an animal model of cognitive function. It had promising results in animal models of obesity and psychosis.
Originator
Sources: http://adisinsight.springer.com/drugs/800023681
Curator's Comment: # Pfizer
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL225 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16949622 |
0.11 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23184281
Rats: rats were used to test the effect of varying doses of
CP-809101 (1–3 mg/kg SC) on nicotine self-administration
according to a repeated-measures design, with each animal receiving each dose and vehicle in a counterbalanced sequence, with 2–4 days between cycles.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26787771
CP-809101 increased mouse renal proximal tubular cells (RPTCs) respiration and peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) mRNA expression in RPTCs at 1-10 nM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:18:39 GMT 2023
by
admin
on
Sat Dec 16 08:18:39 GMT 2023
|
Record UNII |
A2EXW95647
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CP-809101
Created by
admin on Sat Dec 16 08:18:39 GMT 2023 , Edited by admin on Sat Dec 16 08:18:39 GMT 2023
|
PRIMARY | |||
|
A2EXW95647
Created by
admin on Sat Dec 16 08:18:39 GMT 2023 , Edited by admin on Sat Dec 16 08:18:39 GMT 2023
|
PRIMARY | |||
|
9901086
Created by
admin on Sat Dec 16 08:18:39 GMT 2023 , Edited by admin on Sat Dec 16 08:18:39 GMT 2023
|
PRIMARY | |||
|
DTXSID60197369
Created by
admin on Sat Dec 16 08:18:39 GMT 2023 , Edited by admin on Sat Dec 16 08:18:39 GMT 2023
|
PRIMARY | |||
|
479683-64-2
Created by
admin on Sat Dec 16 08:18:39 GMT 2023 , Edited by admin on Sat Dec 16 08:18:39 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |